A Phase 1 interventional study of Esflurbiprofen Topical System in Healthy, sponsored by Teikoku Seiyaku Co., Ltd.. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-22.
Sponsored by Teikoku Seiyaku Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a single-center, open-label, single-dose trial performed in a randomized, four-way, change-over design in healthy volunteers. The primary purpose of this study is to evaluate the effect of moderate heat, occlusion, and moderate exercise on pharmacokinetics. The secondary purpose is to characterize the effect of special conditions on the bioavailability and to evaluate patch adhesion and safety of TK-254RX and a residual amount of the patch.
Teikoku Seiyaku Co., Ltd. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TK-254RX will be applied with no special condition
Drug: Esflurbiprofen Topical System
TK-254RX will be applied with moderate heat
Drug: Esflurbiprofen Topical System
TK-254RX will be applied with occlusion
Drug: Esflurbiprofen Topical System
TK-254RX will be applied with 3 moderate exercise sessions
Drug: Esflurbiprofen Topical System
TK-254RX will be applied for one day
Assessing the effect of each intervention by Area under the plasma concentration versus time curve over 24 hours (AUC0-24) of S-flurbiprofen
assessment of the effect of heat, occlusion, and moderate exercise on Test by use of AUC0-24 of S flurbiprofen
Time frame: Day 1 to Day 2 for each period
Assessing the effect of each intervention by peak plasma concentration (Cmax) of S-flurbiprofen
assessment of the effect of heat, occlusion, and moderate exercise on Test determined by use of Cmax of S flurbiprofen
Time frame: Day 1 to Day 2 for each period
Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to last measurement time point with a concentration value above lower limit of quantitation (AUC0-tlast) of S-flurbiprofen
assessment of the effect of heat, occlusion, and moderate exercise on Test determined by use of AUC0-tlast of S flurbiprofen
Time frame: Day 1 to Day 4 for each period
Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to infinity (AUC0-inf) of S-flurbiprofen
assessment of the effect of heat, occlusion, and moderate exercise on Test determined by use of AUC0-inf of S flurbiprofen
Time frame: Day 1 to Day 4 for each period
Assessing the effect of each intervention by area under the curve over 24 hours (AUC0-24)
Characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by AUC0-24 of R-flurbiprofen and metabolites, if applicable
Time frame: Day 1 to Day 2 for each period
Assessing the effect of each intervention by peak plasma concentration (Cmax)
Characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Cmax of R-flurbiprofen and metabolites, if applicable
Time frame: Day 1 to Day 2 for each period
Assessing the effect of each intervention by area under the plasma concentration versus time curve from patch application to last time point with a concentration value above lower limit of quantitation (AUC0-tlast)
Characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by AUC0-tlast of R-flurbiprofen and metabolites, if applicable
Time frame: Day 1 to Day 4 for each period
Assessing the effect of each intervention by area under plasma concentration versus time curve from patch application to infinity (AUC0-inf)
Characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by AUC0-inf of R-flurbiprofen and metabolites, if applicable
Time frame: Day 1 to Day 4 for each period
Assessing the effect of each intervention by percentage of area under the plasma concentration versus time curve extrapolated to infinity to area under the plasma concentration versus time curve from 0 hour to infinity (AUCexpol%)
characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by AUCexpol% of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable
Time frame: Day 1 to Day 4 for each period
Assessing the effect of each intervention by concentration at the last time point with concentration value above lower limit of quantitation (Clast)
characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Clast of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable
Time frame: Day 1 to Day 2 for each period
Assessing the effect of each intervention by time point to reach peak plasma concentration (Tmax)
characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Tmax of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable
Time frame: Day 1 to Day 4 for each period
Asssessing the effect of each intervention by last time point with concentration value above the lower limit of quantitation (Tlast)
characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Tlast of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable
Time frame: Day 1 to Day 4 for each period
Assessing the effect of each intervention by apparent terminal elimination half-life (T1/2)
characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by T1/2 of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable
Time frame: Day 1 to Day 4 for each period
Assessing the effect of each intervention by apparent terminal elimination rate constant determined by log-linear regression (Lz)
characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Lz of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable
Time frame: Day 1 to Day 4 for each period
Assessing the effect of each intervention by time point before first concentration balue above the lower limit quantitation (Tlag)
characterisation of the effect of heat, occlusion, and moderate exercise on the bioavailability of Test determined by Tlag of S flurbiprofen as well as R flurbiprofen and their metabolites, if applicable
Time frame: Day 1 to Day 2 for each period
Characterization of EFTS adhesion
measuring patch adhesion area by percentage of visually by site staff with remaining patch adhered
Time frame: Day 2 for each period
Characterization of local tolerability
Assessing the local tolerability by using the 8-point dermal response and other effects score according to FDA recommendation
Time frame: with in 5 minutes after removal of each patch as well as 12 hours, 24 hours, and 36 hours after removal for each period
Recording adverse event and serious adverse event
Time frame: Day 1 to Day 4 for each period
Residual amount
residual amout of S-flurbiprofen in used patch for each period
Time frame: Day 2 for each period
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Apr 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Teikoku Seiyaku Co., Ltd.